TABLE 2

Demographics and clinical status of patients based on MSH2 gene sequencea

Patient characteristicbTotal (n = 81)Wild-type MSH2 gene isolates (n = 45)Isolates with MSH2 gene mutations (n = 36)P value
Demographics
    Age (median [IQR]) (yr)71 (0–91)72 (0–90)71 (0–91)0.556
    Male50 (61.7)27 (60.0)23 (63.9)0.819
    Neonate (≤28 days)4 (4.9)2 (4.4)2 (5.6)1
Department
    Medical36 (44.4)19 (42.2)17 (47.2)0.822
    Surgical21 (25.9)12 (26.7)9 (25.0)1
    Onco-hematology3 (3.7)1 (2.2)2 (5.6)0.582
    ICU21 (25.9)13 (28.9)8 (22.2)0.612
Underlying disease
    Cardiovascular disease32 (39.5)18 (40.0)14 (38.9)1
    Neurological disorder15 (18.5)10 (22.2)5 (13.9)0.398
    Chronic renal failure22 (27.2)11 (24.4)11 (30.6)0.619
    Diabetes mellitus18 (22.2)13 (28.9)5 (13.9)0.178
    Pulmonary disease19 (23.5)9 (20.0)10 (27.8)0.440
    Liver disease13 (16.0)8 (17.8)5 (13.9)0.765
    Gastrointestinal disease38 (46.9)20 (44.4)18 (50.0)0.659
    Solid-organ malignancy28 (34.6)14 (31.1)14 (38.9)0.490
    Hematologic malignancy2 (2.5)1 (2.2)1 (2.8)0.694
    Solid-organ transplant1 (1.2)01 (2.8)0.444
    HIV5 (6.2)2 (4.4)3 (8.3)0.651
    Charlson index (median [IQR])6 (0–12)6 (0–10)6 (0–12)0.388
Risk factor
    Central venous catheter64 (79.0)35 (77.8)29 (80.6)0.791
    Total parenteral nutrition44 (54.3)24 (53.3)20 (55.6)1
    Chemotherapy9 (11.1)5 (11.1)4 (11.1)1
    Neutropenia (<500 cells/mm3)2 (2.5)1 (2.2)1 (2.8)1
    Corticosteroids (prior mo)15 (18.5)8 (17.8)7 (19.4)1
    Immunosuppressive therapy4 (4.9)3 (6.7)1 (2.8)0.625
    Surgery33 (40.7)16 (35.6)17 (47.2)0.364
    Abdominal surgery26 (32.1)13 (28.9)13 (36.1)0.633
    Previous antimicrobial use76 (93.8)42 (93.3)34 (94.4)1
Antifungal use
    Previous AF used17 (22.4)9 (22.0)8 (22.9)1
    Voriconazole2 (2.5)2 (4.4)00.5
    Fluconazole15 (18.5)7 (15.6)8 (22.2)0.567
    Echinocandins4 (4.9)1 (2.2)3 (8.3)0.318
    Amphotericin B1 (1.2)1 (2.2)01
    Duration of AF (days)15 (3–63)21 (9–44)14.5 (3–63)0.933
    Time from previous AF to episode (days)1 (−11–73)0 (−6–73)2.5 (−11–73)0.755
    Breakthrough fungemia7 (8.6)3 (6.7)4 (11.1)0.694
    Fluconazole resistance4 (4.9)2 (4.4)2 (5.6)1
Clinical manifestation
    Septic shock24 (29.6)18 (40.0)6 (16.7)0.028
    Pitt score (median [IQR])1 (0–12)2 (0–10)0 (0–12)0.093
Infection source
    Primary14 (17.3)9 (20.0)5 (13.9)0.562
    Central venous catheter27 (33.3)18 (40.0)9 (25.0)0.235
    Urinary tract4 (4.9)3 (6.7)1 (2.8)0.625
    Abdomen28 (34.6)14 (31.1)14 (38.9)0.490
    Other3 (3.7)03 (8.3)0.084
    Unknown5 (6.2)1 (2.2)4 (11.1)0.166
Therapeutic management
    No antifungals14 (17.3)9 (20.0)5 (13.9)0.562
    Echinocandin as initial AF29 (43.3)15 (41.7)14 (45.2)0.809
    Adequate targeted AF62 (76.5)34 (75.6)28 (77.8)1
    Infection source control56 (81.2)31 (81.6)25 (80.6)1
Outcomes
    Metastatic complications13 (18.1)6 (15.0)7 (21.9)0.543
    ICU due to candidemia10 (12.3)6 (13.3)4 (11.1)1
    7-day mortality13 (16.0)10 (22.2)3 (8.3)0.129
    30-day mortality24 (29.6)18 (40.0)6 (16.7)0.028
    Mortality >30 days11 (13.6)5 (11.1)6 (16.7)0.526
    Overall mortality35 (43.2)23 (51.1)12 (33.3)0.121
    Hospital length of stay (days)26 (0–165)25 (0–165)26.5 (0–112)0.711
  • a All data reported as number (%), unless otherwise specified.

  • b IQR, interquartile range; ICU, intensive care unit; HIV, human immunodeficiency virus; AF, antifungal.